Agomelatine for depression: expanding the horizons?

Area of Science:

• Pharmacology
• Neuroscience
• Psychiatry

Background:

• Agomelatine is an antidepressant with dual action: melatonin receptor agonism and selective serotonin antagonism.
• Its mechanism aids in resynchronizing disrupted circadian rhythms, improving sleep patterns.
• The review focuses on agomelatine's efficacy in depression comorbid with somatic disorders.

Purpose of the Study:

• To review the efficacy of agomelatine in treating depression associated with specific medical illnesses.
• To assess agomelatine's effectiveness in conditions such as Parkinson's disease, cardiovascular illness, and type II diabetes.
• To explore its potential benefits for bipolar depression, seasonal affective disorder, and anhedonia symptoms.

Main Methods:

• Literature review from 2000 to August 2018 using Scopus and Web of Science.
• Keywords used: agomelatine, depression, medical illness.
• Focused on studies examining depression in Parkinson's disease, cardiovascular illness, and type II diabetes.

Main Results:

• Agomelatine demonstrates efficacy in treating depression comorbid with Parkinson's disease, cardiovascular illness, and type II diabetes.
• Potential benefits were observed for bipolar depression, seasonal affective disorder, and anhedonia.
• Continuation studies suggest sustained clinical response.

Conclusions:

• Agomelatine offers a unique therapeutic option for depression, particularly when comorbid with somatic disorders.
• Long-term efficacy and potential hepatotoxicity remain key considerations, necessitating regular laboratory testing.
• Despite regulatory approval in some regions, its use is limited by factors including US registration denial.